更新時間:2023-07-28
Kerafast抗體Anti-DNA-RNA Hybrid [S9.6] :Anti-DNA-RNA Hybrid [S9.6] Antibody recognizes RNA-DNA hybrids of various lengths.
特色:
可用于檢測 R 環
對 DNA-RNA 雜交體(ti)的高特異(yi)性和(he)親和(he)力
不與單鏈 DNA 或雙鏈 DNA 發生交叉反應
對于富(fu)含 AU 的(de)(de)雙(shuang)鏈 RNA,觀察到了輕(qing)微的(de)(de)交叉反應(約 5 倍以下)。
長度為 8、10、15 和 23 個堿基對的雜(za)交體顯示出高親和力結合
DNA-RNA 雜(za)(za)合體是真核細胞中的(de)一(yi)種自然現象,這些雜(za)(za)合體的(de)水(shui)平(ping)在具有高轉錄活性的(de)位(wei)點增(zeng)加,例如在轉錄起始、抑(yi)制和(he)延伸期(qi)間。由(you)于 RNA-DNA 雜(za)(za)合體會影響基因組的(de)不穩定性,因此(ci) S9.6 抗體是一(yi)種有用(yong)的(de)試劑,可幫助研究在 DNA 復制或其他細胞過程中由(you)這些雜(za)(za)合體形成的(de) R 環和(he)損傷的(de)后果。此(ci)外(wai),S9.6 抗體可有效識別用(yong)于微陣(zhen)列研究的(de) RNA-DNA 雜(za)(za)交。
This mouse monoclonal antibody was generated against a ΦX174 bacteriophage-derived synthetic DNA–RNA antigen and recognizes RNA-DNA hybrids of various lengths.
Highlights:
* Useful in the detection of R-loops
* High specificity and affinity for DNA-RNA hybrids
* Does NOT cross-react with single-stranded DNA or double-stranded DNA
* Minor cross-reaction (~5-fold less) has been observed for AU-rich double-stranded RNA.
* High affinity binding shown for hybrids of 8, 10, 15, and 23 base pairs in length
產品(pin)詳(xiang)情:
Product Type: | Antibody |
Name: | Anti-DNA-RNA Hybrid [S9.6] |
Antigen: | S9.6 ΦX174 bacteriophage-derived synthetic DNA–RNA antigen |
Isotype: | Rabbit IgG |
Fusion Tag(s): | Mouse Fab version contains His-tag |
Clone Name: | S9.6 |
Reactivity: | High specificity and affinity for DNA/RNA hybrids and other A-form nucleic acid hybrids |
Immunogen: | ΦX174 bacteriophage-derived synthetic DNA/RNA |
Purification Method: | Protein A/G |
Buffer: | ENHOO1: PBS, 0.05% (w/v) Sodium Azide Ab01137- : PBS with 0.02% Proclin 300 |
Tested Applications: | Dot Blot Analysis: 0.2 µg/mL. |
參考文(wen)獻:
1. Dutrow N, Nix DA, Holt D, Milash B, Dalley B, Westbroek E, Parnell TJ, Cairns BR. Dynamic transcriptome of Schizosaccharomyces pombe shown by RNA-DNA hybrid mapping. Nat Genet. 2008 Aug;40(8):977-86.
2. Bhatia V, Barroso SI, García-Rubio ML, Tumini E, Herrera-Moyano E, Aguilera A. BRCA2 prevents R-loop accumulation and associates with TREX-2 mRNA export factor PCID2. Nature. 2014 Jul 17;511(7509):362-5.
3. Lim J, Giri PK, Kazadi D, Laffleur B, Zhang W, Grinstein V, Pefanis E, Brown LM, Ladewig E, Martin O, Chen Y, Rabadan R, Boyer F, Rothschild G, Cogné M, Pinaud E, Deng H, Basu U. Nuclear Proximity of Mtr4 to RNA Exosome Restricts DNA Mutational Asymmetry. Cell. 2017 Apr 20;169(3):523-537.e15.
4. Lang KS, Hall AN, Merrikh CN, Ragheb M, Tabakh H, Pollock AJ, Woodward JJ, Dreifus JE, Merrikh H. Replication-Transcription Conflicts Generate R-Loops that Orchestrate Bacterial Stress Survival and Pathogenesis. Cell. 2017 Aug 10;170(4):787-799.e18.
5. De Cecco M, Ito T, Petrashen AP, Elias AE, Skvir NJ, Criscione SW, Caligiana A, Brocculi G, Adney EM, Boeke JD, Le O, Beauséjour C, Ambati J, Ambati K, Simon M, Seluanov A, Gorbunova V, Slagboom PE, Helfand SL, Neretti N, Sedivy JM. L1 drives IFN in senescent cells and promotes age-associated inflammation. Nature. 2019 Feb;566(7742):73-78.
6. Herold S, Kalb J, Büchel G, Ade CP, Baluapuri A, Xu J, Koster J, Solvie D, Carstensen A, Klotz C, Rodewald S, Schülein-V?lk C, Dobbelstein M, Wolf E, Molenaar J, Versteeg R, Walz S, Eilers M. Recruitment of BRCA1 limits MYCN-driven accumulation of stalled RNA polymerase. Nature. 2019 Mar;567(7749):545-549
7. Sanz LA, Chédin F. High-resolution, strand-specific R-loop mapping via S9.6-based DNA-RNA immunoprecipitation and high-throughput sequencing. Nat Protoc. 2019 Jun;14(6):1734-1755.
8. Graf M, Bonetti D, Lockhart A, Serhal K, Kellner V, Maicher A, Jolivet P, Teixeira MT, Luke B. Telomere Length Determines TERRA and R-Loop Regulation through the Cell Cycle. Cell. 2017 Jun 29;170(1):72-85.e14.
9. Gorthi A, Romero JC, Loranc E, Cao L, Lawrence LA, Goodale E, Iniguez AB, Bernard X, Masamsetti VP, Roston S, Lawlor ER, Toretsky JA, Stegmaier K, Lessnick SL, Chen Y, Bishop AJR. EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma. Nature. 2018 Mar 15;555(7696):387-391.